Intrommune Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Intrommune Therapeutics's estimated annual revenue is currently $3.1M per year.
- Intrommune Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Intrommune Therapeutics has 20 Employees.
- Intrommune Therapeutics grew their employee count by 11% last year.
Intrommune Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $1.1M | 7 | 250% | N/A | N/A |
#2 | $5.9M | 38 | 15% | N/A | N/A |
#3 | $34.7M | 224 | 6% | N/A | N/A |
#4 | $5.2M | 67 | 0% | $10M | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.5M | 37 | 0% | $51.6M | N/A |
#7 | $0.9M | 6 | -14% | N/A | N/A |
#8 | $4.3M | 21 | -16% | $3.3M | N/A |
#9 | $4.2M | 27 | -16% | N/A | N/A |
#10 | $4.3M | 56 | -8% | $118M | N/A |
What Is Intrommune Therapeutics?
Intrommune Therapeutics is a specialty biopharmaceutical company located in New York, NY. Intrommune is developing a revolutionary new treatment platform for food allergies that is safe, effective and convenient. Intrommune's first product is a therapy for patients who suffer from peanut allergy. Intrommune is developing the oral mucosal immunotherapy (OMIT) platform for food allergies. It is a long-term solution for the 220 million, including 9 million U.S. adults and 6 million U.S. children, who suffer from this life-altering condition.
keywords:N/AN/A
Total Funding
20
Number of Employees
$3.1M
Revenue (est)
11%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Intrommune Therapeutics News
Intrommune Expands Study Scope to Explore MTD. NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based,...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.1M | 20 | -46% | $25.1M |
#2 | $2M | 20 | 18% | N/A |
#3 | $2M | 20 | -20% | N/A |
#4 | $3.5M | 20 | -46% | N/A |
#5 | $3.1M | 20 | -17% | N/A |